Lanreotide Autogel® for Acromegaly
Tóm tắt
Since their introduction into clinical practice, somatostatin analogs have been the pharmacological therapy of choice for the treatment of acromegaly. The first preparations of somatostatin analogs available for clinical use were administered subcutaneously two or three times daily, which was not optimal with respect to patient compliance. The introduction of long-acting formulations of somatostatin analogs has overcome this inconvenience. Lanreotide Autogel®, a new viscous, supersaturated, aqueous solution of lanreotide, is available in a prefilled syringe and administered by deep subcutaneous injection every 28 days. Lanreotide Autogel® has different pharmacokinetic properties from the earlier lanreotide slow-release (SR) formulation, which may account for its better tolerability. Furthermore, lanreotide Autogel® is at least as efficacious as the other somatostatin analogs in lowering growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels in the majority and in restoring safe GH and age-normalized IGF-1 levels in about 50–60% of patients with acromegaly. In conclusion, lanreotide Autogel® is a valuable new addition to the acromegaly treatment armamentarium. Patients receiving intramuscular lanreotide SR injections every 7–14 days can be switched to an appropriate dose of deep subcutaneous lanreotide Autogel® every 28 days, without any impact on safety or loss of efficacy.
Tài liệu tham khảo
Guillemin R, Gerich JE. Somatostatin: physiological and clinical significance. Annu Rev Med 1976; 27: 379–88
Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991 Nov; 12(4): 450–82
Reichlin S. Somatostatin. N Engl J Med 1983; 309(24): 1495–501
Reichlin S. Somatostatin (second of two parts). N Engl J Med 1983; 309(25): 1556–63
Melmed S, Jackson I, Kleinberg D, et al. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998 Aug; 83(8): 2646–52
Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982 Sep 13; 31(11): 1133–40
Raynor K, Murphy WA, Coy DH, et al. Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol Pharmacol 1993 Jun; 43(6): 838–44
Data on file, Beaufour-Ipsen Laboratories, Slough, 2001
Heron I, Thomas F, Dero M, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993 Mar; 76(3): 721–7
Kuhn JM, Legrand A, Ruiz JM, et al. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 1994 Sep; 38(3): 213–9
Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002 Jan; 87(1): 99–104
Beckers A. Pituitary adenomas [on CD-ROM]. 3rd ed. Liège: Graphmed Ltd, 2003
Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003 Feb; 24(1): 28–47
Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1994 Dec; 135(6): 2814–7
Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002 Jul; 87(7): 3013–8
Shimon I, Melmed S. Structure and function of somatostatin receptors in growth hormone control. J Endocrinol 1997 Oct; 155Suppl. 1: S3–6
Panetta R, Patel YC. Expression of mRNA for all five human somatostatin receptors (hsstr1–5) in pituitary tumors. Life Sci 1995; 56(5): 333–42
Baldelli R, Colao A, Razzore P, et al. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30mg). J Clin Endocrinol Metab 2000 Nov; 85(11): 4099–103
Colao A, Marzullo P, Ferone D, et al. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 1999 Jan; 22(1): 40–7
Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 2000 Nov; 53(5): 577–86
Caron P, Morange-Ramos I, Cogne M, et al. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997 Jan; 82(1): 18–22
Sheppard MC. Primary medical therapy for acromegaly. Clin Endocrinol 2003 Apr; 58(4): 387–99
Rohrer SP, Birzin ET, Mosley RT, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998 Oct 23; 282(5389): 737–40
Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000 Feb; 85(2): 526–9
Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994 Jul; 41(1): 95–102
Colao A, Balzano A, Ferone D, et al. Increased prevalence of colonie polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. Clin Endocrinol (Oxf) 1997 Jul; 47(1): 23–8
Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998 Aug; 83(8): 2730–4
Bates AS, Van’t Hoff W, Jones JM, et al. An audit of outcome of treatment in acromegaly. Q J Med 1993 May; 86(5): 293–9
Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992 Sep; 21(3): 669–92
Stevenaert A, Beckers A. Presurgical octreotide: treatment in acromegaly. Metabolism 1996 Aug; 45(8 Suppl. 1): 72–4
Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998 Sep; 83(9): 3034–40
Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001 Jun; 86(6): 2779–86
Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients: a clinical research center study. J Clin Endocrinol Metab 1995 Sep; 80(9): 2768–75
Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly: a randomized, multicenter study. Ann Intern Med 1992 Nov; 117(9): 711–8
Lancranjan I, Atkinson AB. Results of a European multicentre study with Sando-statin LAR in acromegalic patients: Sandostatin LAR Group. Pituitary 1999; 1(2): 105–14
Davies PH, Stewart SE, Lancranjan L, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998 Mar; 48(3): 311–6